metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus gp100
	ipilimumab alone vs. gp100	1	0.66 [0.51; 0.86], 1 RCT, I2=0% conclusive unassessable degree of certainty	-	-
	ipilimumab plus gp100 vs. gp100	1	0.68 [0.55; 0.85], 1 RCT, I2=0% conclusive unassessable degree of certainty	-	-
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1	0.84 [0.71; 1.00], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.89 [0.66; 1.21], 1 RCT, I2=0% inconclusive result	-
	ipilimumab plus gp100 vs. ipilimumab alone	1	1.04 [0.83; 1.30], 1 RCT, I2=0% inconclusive result	-	-
versus placebo plus SoC
	ipilimumab plus SoC vs. placebo plus SoC	1	0.72 [0.59; 0.87], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.76 [0.63; 0.92], 1 RCT, I2=0% conclusive unassessable degree of certainty	-